Skip to main content

Table 1 Demographics of acute graph-versus-host disease patients receiving mesenchymal stromal cell therapy

From: Tissue immune profiles supporting response to mesenchymal stromal cell therapy in acute graft-versus-host disease—a gut feeling

CharacteristicRespondersNon-respondersP value
Total number of patients88 
Age at HSCT (years): median (min–max)58.4 (34.0–64.9)54.3 (13.5–65.8)0.96a
Female sex: N (%)4 (50)2 (25)0.61b
Underlying disease: N (%)
 Myeloid neoplasm4 (50)7 (87.5)0.35b
 Lymphoid neoplasm2 (25)1 (12.5)
 Plasma cell dyscrasia1 (12.5)0 (0)
 Prostate cancer1 (12.5)0 (0)
Donor: N (%)
 HLA-identical sibling5 (62.5)5 (62.5)1b
 Matched unrelated donor3 (37.5)3 (37.5)
Conditioning: N (%)
 Standard5 (62.5)6 (75)1b
 Reduced intensity (RIC)3 (37.5)2 (25)
Timeline (days): median (min–max)
 Time from HSCT or DLI to aGVHD32.5 (13–107)35.5 (11–169)0.96a
 Time from aGVHD diagnosis to steroid treatment1.5 (0–7)1 (0–7)0.91a
 Time from steroid treatment to MSC treatment8 (3–44)15 (4–55)0.17a
 Time from steroid treatment to biopsy#2 (0–13)6 (1–29)0.18a
 Biopsy before initiation of steroid treatment (N)101b
 Time from biopsy to MSC treatment5.5 (2–37)9.5 (3–26)0.34a
aGVHD global clinical classification: N (%)
 Grades 0–I0 (0)0 (0)NA
 Grade II0 (0)0 (0)
 Grades III–IV8 (100)8 (100)
GI aGVHD pathological classification: N (%)
 Grades 0–I0 (0)3 (37.5)0.077b
 Grade II0 (0)1 (12.5)
 Grades III–IV8 (100)4 (50)
CMV infection: N (%)
 CMV colitis2 (25)3 (37.5)1b
 CMV viremia (> 1000 copies/ml)2 (25)4 (50)0.61b
Leukocyte counts at time of biopsy: Mean (± SD)
 Total leukocytes (× 109)/L)11.26 (± 1.86)9.86 (± 8.28)1a
 Neutrophils (× 109/L)8.98 (± 1.81)7.79 (± 6.54)1a
 Eosinophils (× 109/L)0.04 (± 0.07)0.05 (± 0.09)0.82a
 Basophils (× 109/L)0.01 (± 0.01)0.05 (± 0.09)0.65a
 Lymphocytes (× 109/L)0.90 (± 0.66)0.63 (± 0.49)0.60a
 Monocytes (× 109/L)1.00 (± 0.70)1.19 (± 1.47)0.84a
  1. aWilcoxon rank-sum test
  2. bFisher’s exact test
  3. #Excluding patients that were biopsied before steroid treatment
  4. Samples taken > 6 days from date of biopsy are excluded
  5. GI gastro-intestinal, CMV cytomegalovirus, MSC mesenchymal stromal cell, aGVHD acute graft-versus-host disease, DLI donor lymphocyte infusion, HSCT hematopoietic stem cell transplantation, NA not available, aHSCT allogeneic hematopoietic stem cell transplantation, HLA human leukocyte antigen, RIC reduced intensity conditioning, DLI donor lymphocyte infusion, SEM standard error of the mean